• [email protected]
Speratum Biopharma, Inc.
  • Our Story
  • OurTechnology
    • miR-198 Platform
    • NoPass Platform
    • Nano-In Platform
    • NM-198 Platform
    • Publications
    • Development Plan
  • OurTeam
    • Board of Directors
  • OurOpportunities
    • Physicians
    • Collaborators
    • Investors
    • Careers
    • FAQ

Category: Uncategorized

  • Home
  • Uncategorized
16Dec
  • Posted on December 16, 2024
  • Speratum Biopharma Admin
  • No Comments

State-of-Art in mRNA Therapeuticsand Gene Delivery

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

MicroRNAs: Control and Loss of Control in Human Physiology and Disease

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

Current advances in research and clinical applications of PLGA-based nanotechnology

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer 

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

New Polymer of lactic-co-glycolic acid-modified Polyethylenimine for Nucleic Acid Delivery

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

Sa1112: Therapeutic potential of miR-198 to suppress MC38 colonic adenocarcinoma growth.

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

A novel miR-198-based mimic as a potential therapeutic against pancreatic ductal adenocarcinoma (PDAC).

Read More
21Nov
  • Posted on November 21, 2024
  • Speratum Biopharma Admin
  • No Comments

MiR-198 sensitizes pancreatic cancer to gemcitabine treatment through downregulation of VCP-mediated autophagy maturation.

Read More

Posts navigation

1 2

Recent Posts

  • State-of-Art in mRNA Therapeuticsand Gene Delivery

    December 16, 2024
  • MicroRNAs: Control and Loss of Control in Human Physiology and Disease

    November 21, 2024
  • Current advances in research and clinical applications of PLGA-based nanotechnology

    November 21, 2024

Categories

  • Uncategorized

Looking for volunteer job

Be a Volunteer

Useful Links

  • Our Story
  • OurTechnology
    • miR-198 Platform
    • NoPass Platform
    • Nano-In Platform
    • NM-198 Platform
    • Publications
    • Development Plan
  • OurTeam
    • Board of Directors
  • OurOpportunities
    • Physicians
    • Collaborators
    • Investors
    • Careers
    • FAQ

© 2025 Speratum. All rights reserved.

  • Terms of Agreement
  • Privacy Policy
  • Useful Links
Speratum Biopharma, Inc.
We Value Your Privacy

At Speratum Biopharma, Inc., we use cookies and similar technologies to enhance your experience on our website, analyze site traffic, and personalize content. By clicking "Accept," you consent to the use of these technologies as described in our Privacy Policy.

Functional Always active
We process your personal information to measure and improve our sites and service, to assist our marketing campaigns and to provide personalised content and advertising. By clicking the button on the right, you can exercise your privacy rights. For more information see our privacy notice
Preferences
We process your personal information to measure and improve our sites and service, to assist our marketing campaigns and to provide personalised content and advertising. By clicking the button on the right, you can exercise your privacy rights. For more information see our privacy notice
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
We process your personal information to measure and improve our sites and service, to assist our marketing campaigns and to provide personalised content and advertising. By clicking the button on the right, you can exercise your privacy rights. For more information see our privacy notice
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}